Table 3b.
System Organ Class | Term | Grade | Relationship to Treatment | Days from Concurrent RX start |
---|---|---|---|---|
General disorders and administration site conditions | Fatigue | 3 | Probable | 105 |
Metabolism and nutrition disorders | Hypomagnesemia | 4 | Possible | 183 |
Hypokalemia | 3 | Possible | 168 | |
Respiratory, thoracic and mediastinal disorders | Epistaxis* | 3 | Probable | 176 |
Nervous system disorders | Headache | 3 | Probable | 98 |
Metabolism and nutrition disorders | Hyponatremia | 3 | Possible | 98 |
Vascular disorders | Hot flashes | 3 | Definite | 300 |
General disorders and administration site conditions | Pain | 3 | Possible | 180 |
Ear and labyrinth disorders | Hearing impaired | 3 | Probable | 333 |
Metabolism and nutrition disorders | Hypokalemia | 4 | Probable | 136 |
Nervous system disorders | Neuralgia | 3 | Possible | 126 |
Infections and infestations | Skin infection | 3 | Possible | 126 |
probably attributable to bevacizumab
Key: RX=treatment